Evidence map›Paper›PMID 36329614›Full record

ArticleJournal of medical virology2023

Bovine lactoferrin inhibits SARS-CoV-2 and SARS-CoV-1 by targeting the RdRp complex and alleviates viral infection in the hamster model.

Shi-Ting He, Hongbo Qin, Lin Guan, Ke Liu, Bixia Hong, Xiaoxu Zhang, Fuxing Lou, Maochen Li, Wei Lin, Yangzhen Chen and 9 more

Open access · greenAbstract read
In one paragraph

Article in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Advancements in the Development of Anti-SARS-CoV-2 Therapeutics.International journal of molecular sciences · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Potential of Lactoferrin in the Treatment of Lung Diseases.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Shi-Ting HeCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Hongbo QinCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Lin GuanCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Ke LiuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Bixia HongCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Xiaoxu ZhangBeijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China.
Fuxing LouCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Maochen LiCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Wei LinCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Yangzhen ChenCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Chengzhi HeBeijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China.ORCID 0000-0001-5013-0207
Feitong LiuH&H Group, H&H Research, China Research and Innovation, Guangzhou, China.
Shanshan LuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Shengdong LuoThe Fifth Medical Center, Chinese PLA People's Liberation Army General Hospital, Beijing, China.
Shaozhou ZhuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Xiaoping AnCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Lihua SongCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Huahao FanCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Yigang TongCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Beijing University of Chemical Technology · CNPeople's Liberation Army No. 150 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast milk has been found to inhibit coronavirus infection, while the key components and mechanisms are unknown. We aimed to determine the components that contribute to the antiviral effects of breastmilk and explore their potential mechanism. Lactoferrin (Lf) and milk fat globule membrane inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related coronavirus GX_P2V and transcription- and replication-competent SARS-CoV-2 virus-like particles in vitro and block viral entry into cells. We confirmed that bovine Lf (bLf) blocked the binding between human angiotensin-converting enzyme 2 and SARS-CoV-2 spike protein by combining receptor-binding domain (RBD). Importantly, bLf inhibited RNA-dependent RNA polymerase (RdRp) activity of both SARS-CoV-2 and SARS-CoV in vitro in the nanomolar range. So far, no biological macromolecules have been reported to inhibit coronavirus RdRp. Our result indicated that bLf plays a major role in inhibiting viral replication. bLf treatment reduced viral load in lungs and tracheae and alleviated pathological damage. Our study provides evidence that bLf prevents SARS-CoV-2 infection by combining SARS-CoV-2 spike protein RBD and inhibiting coronaviruses' RdRp activity, and may be a promising candidate for the treatment of coronavirus disease 2019.

Indexed as

COVID-19SARS-CoV-2Antiviral AgentsCricetinaeFemaleHumansLactoferrinRNA-Dependent RNA PolymeraseSpike Glycoprotein, CoronavirusAntiviral AgentsLactoferrinRNA-Dependent RNA PolymeraseSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2coronaviruslactoferrinRNA-dependent RNA polymeraseSARS-CoV-2

Identifiers

PMID36329614
PMCPMC9878033
OpenAlexW4308185380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.